Dana Tegzová

2.9k total citations · 2 hit papers
22 papers, 2.1k citations indexed

About

Dana Tegzová is a scholar working on Rheumatology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dana Tegzová has authored 22 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 7 papers in Immunology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dana Tegzová's work include Systemic Lupus Erythematosus Research (13 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Dana Tegzová is often cited by papers focused on Systemic Lupus Erythematosus Research (13 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Rheumatoid Arthritis Research and Therapies (5 papers). Dana Tegzová collaborates with scholars based in Czechia, United States and Brazil. Dana Tegzová's co-authors include William W. Freimuth, William Stohl, Douglas R. Hough, Winn Chatham, Z. John Zhong, Daniel J. Wallace, Omid Zamani, Michelle Petri, Richard Furie and Ellen M. Ginzler and has published in prestigious journals such as Frontiers in Immunology, Annals of the Rheumatic Diseases and Arthritis & Rheumatology.

In The Last Decade

Dana Tegzová

21 papers receiving 2.0k citations

Hit Papers

A phase III, randomized, placebo-controlled study of beli... 2011 2026 2016 2021 2011 2013 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
    2011 1.1k citations Richard Furie, Michelle Petri et al. Arthritis & Rheumatism profile →
  2. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
    2013 456 citations Désirée van der Heijde, Yoshiya Tanaka et al. Arthritis & Rheumatism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dana Tegzová Czechia 15 1.7k 1.0k 657 341 250 22 2.1k
Omid Zamani United States 6 1.5k 0.9× 1.3k 1.3× 641 1.0× 261 0.8× 260 1.0× 12 2.1k
Agneta Zickert Sweden 28 1.6k 0.9× 1.2k 1.1× 363 0.6× 239 0.7× 184 0.7× 56 2.0k
Raymond F. Lum United States 16 1.4k 0.8× 722 0.7× 461 0.7× 148 0.4× 132 0.5× 17 2.0k
C Tănăsescu Romania 11 1.3k 0.8× 1.0k 1.0× 652 1.0× 100 0.3× 149 0.6× 41 1.8k
William Shergy United States 19 1.2k 0.7× 561 0.6× 274 0.4× 481 1.4× 213 0.9× 24 1.9k
Alf Kastbom Sweden 28 1.3k 0.8× 574 0.6× 645 1.0× 251 0.7× 156 0.6× 84 2.0k
Michelle Petri United States 17 1.4k 0.9× 1.2k 1.1× 258 0.4× 228 0.7× 213 0.9× 18 2.1k
Paz Lavilla Spain 7 1.9k 1.1× 1.0k 1.0× 433 0.7× 287 0.8× 72 0.3× 8 2.1k
Raymond E. Felgar United States 22 813 0.5× 1.4k 1.3× 682 1.0× 271 0.8× 486 1.9× 38 2.8k
AO. Aydintug Türkiye 7 1.9k 1.1× 1.0k 1.0× 436 0.7× 246 0.7× 72 0.3× 11 2.2k

Countries citing papers authored by Dana Tegzová

Since Specialization
Citations

This map shows the geographic impact of Dana Tegzová's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Tegzová with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Tegzová more than expected).

Fields of papers citing papers by Dana Tegzová

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana Tegzová. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Tegzová. The network helps show where Dana Tegzová may publish in the future.

Co-authorship network of co-authors of Dana Tegzová

This figure shows the co-authorship network connecting the top 25 collaborators of Dana Tegzová. A scholar is included among the top collaborators of Dana Tegzová based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana Tegzová. Dana Tegzová is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sheikh, Saira Z., James Cheng‐Chung Wei, Dana Tegzová, et al.. (2022). POS0712 YEAR-4 OBSERVATIONAL FOLLOW-UP OF BELIMUMAB SAFETY (MORTALITY AND MALIGNANCIES) IN PATIENTS WITH SLE WHO COMPLETED A PHASE 4, 52-WEEK, RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED SAFETY STUDY. Annals of the Rheumatic Diseases. 81. 637–638. 1 indexed citations
2.
Scheinberg, Morton, James Cheng‐Chung Wei, Dana Tegzová, et al.. (2021). AB0288 SAFETY OF BELIMUMAB IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: YEAR 2 FOLLOW-UP OF A LARGE PHASE 4, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY. Annals of the Rheumatic Diseases. 80. 1170–1171. 1 indexed citations
3.
Cerezo, Lucie Andrés, Hana Hulejová, Michal Tomčík, et al.. (2021). IL-40: A New B Cell-Associated Cytokine Up-Regulated in Rheumatoid Arthritis Decreases Following the Rituximab Therapy and Correlates With Disease Activity, Autoantibodies, and NETosis. Frontiers in Immunology. 12. 745523–745523. 25 indexed citations
4.
Strand, Vibeke, Désirée van der Heijde, Yoshiya Tanaka, et al.. (2020). Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.. PubMed. 38(5). 848–857. 14 indexed citations
5.
6.
Pleštilová, Lenka, Olga Kryštůfková, Dana Tegzová, et al.. (2017). Molecular markers of systemic autoimmune disorders: the expression of MHC-located HSP70 genes is significantly associated with autoimmunity development.. PubMed. 35(1). 33–42. 16 indexed citations
7.
Tegzová, Dana, Jakub Závada, Marta Olejarová, et al.. (2013). FRI0262 Differences in serum microrna profile in active systemic lupus erythematosus and healthy controls. Annals of the Rheumatic Diseases. 72. A463–A463. 1 indexed citations
8.
Heijde, Désirée van der, Yoshiya Tanaka, Roy Fleischmann, et al.. (2013). Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study. Arthritis & Rheumatism. 65(3). 559–570. 456 indexed citations breakdown →
9.
Heijde, D. van der, Yoshiya Tanaka, R Fleischmann, et al.. (2012). Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study. Arthritis & Rheumatism. 64(10). 4 indexed citations
10.
Chatham, Winn, Daniel J. Wallace, William Stohl, et al.. (2012). Effect of Belimumab on Vaccine Antigen Antibodies to Influenza, Pneumococcal, and Tetanus Vaccines in Patients with Systemic Lupus Erythematosus in the BLISS-76 Trial. The Journal of Rheumatology. 39(8). 1632–1640. 66 indexed citations
11.
Doria, Alessandro, Jorge Sánchez‐Guerrero, Dana Tegzová, et al.. (2012). SAT0188 Early clinical improvement in SLE patients treated with belimumab. Annals of the Rheumatic Diseases. 71. 535–535.
12.
Furie, Richard, Michelle Petri, Omid Zamani, et al.. (2011). A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 63(12). 3918–3930. 1143 indexed citations breakdown →
13.
Závada, Jakub, Petra Nytrová, K.P. Wandinger, et al.. (2011). Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatology International. 33(1). 259–263. 30 indexed citations
14.
Vı́tek, Libor, Lucie Muchová, Eva Jančová, et al.. (2010). Association of systemic lupus erythematosus with low serum bilirubin levels. Scandinavian Journal of Rheumatology. 39(6). 480–484. 29 indexed citations
15.
Novota, Peter, et al.. (2010). HLA class II, MICA and PRL gene polymorphisms: the common contribution to the systemic lupus erythematosus development in Czech population. Rheumatology International. 31(9). 1195–1201. 17 indexed citations
16.
Závada, Jakub, Romana Ryšavá, Marta Olejarová, et al.. (2010). Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 19(11). 1281–1289. 87 indexed citations
17.
Olejarová, Marta, et al.. (2009). Magnetic resonance volumetry of pathological brain foci in patients with systemic lupus erythematosus.. PubMed. 26(4). 604–10. 7 indexed citations
18.
Pavelká, Karel, J Gatterová, Dana Tegzová, et al.. (2008). Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment.. PubMed. 25(4). 540–5. 14 indexed citations
19.
Hulínská, D, et al.. (2002). Seronegative Lyme Arthritis caused by Borrelia garinii. Clinical Rheumatology. 21(4). 330–334. 21 indexed citations
20.
Dostál, C, Vladimı́r Tesař, Ivan Rychlík, et al.. (1998). Effect of 1 year cyclosporine a treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus. 7(1). 29–36. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Omid Zamani Breakdown of academic impact, for papers by Agneta Zickert Breakdown of academic impact, for papers by Raymond F. Lum Breakdown of academic impact, for papers by C Tănăsescu Breakdown of academic impact, for papers by William Shergy Breakdown of academic impact, for papers by Alf Kastbom Breakdown of academic impact, for papers by Michelle Petri Breakdown of academic impact, for papers by Paz Lavilla Breakdown of academic impact, for papers by Raymond E. Felgar Breakdown of academic impact, for papers by AO. Aydintug
Rankless by CCL
2026